FIRST AMENDMENT TO LICENSE AGREEMENT

Contract Categories: Intellectual Property - License Agreements
EX-10.28 2 dex1028.htm FIRST AMENDMENT TO LICENSE AGREEMENT First Amendment to License Agreement

Exhibit 10.28

FIRST AMENDMENT TO LICENSE AGREEMENT

This First Amendment to License Agreement (this “Amendment”) is dated effective as of July 7, 2009 (the “First Amendment Effective Date”) by and between The General Hospital Corporation, a Massachusetts not-for-profit corporation doing business as Massachusetts General Hospital (“GENERAL”) and Dara Therapeutics, Inc. (formerly Dara Pharmaceuticals, Inc.), a North Carolina corporation (“COMPANY”).

WHEREAS, GENERAL and COMPANY are parties to that certain License Agreement dated effective May 3, 2004, (the “License Agreement”) and desire to amend the License Agreement, as provided herein.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:

1. Definition of Terms. All capitalized terms contained herein and not otherwise defined shall be defined as provided in the License Agreement.

2. Amendments.

a. Section 1.6 is deleted in its entirety and replaced with the following:

“The term “PATENT RIGHTS” shall mean the patent applications and patents set forth in Appendix A, any and all patents issuing from or based on such patent applications, any and all foreign counterparts of such applications and patents, and any and all continuations, continuations in part, divisions, reissues, reexaminations, extensions, supplementary protection certificates and renewals of any of such patent applications, patents and foreign counterparts.”

b. Appendix A of the License Agreement is deleted in its entirety and replaced by the new Appendix A attached hereto.

3. Full Force and Effect; Conflicts. The License Agreement and its appendices and exhibits remain unmodified and in full force and effect, except as modified hereby, the parties specifically intending the Amendments listed in Section 2 to supersede, amend and supplement the License Agreement and its appendices and exhibits.

4. Successors and Assigns. The License Agreement, as amended by this Amendment, shall be binding upon and inure to the benefit of the parties thereto and their respective permitted successors and assigns.

5. Multiple Counterparts. This Amendment may be executed in multiple counterpart signature pages, each of which when taken together shall constitute one and the same Amendment. This Amendment may be executed by exchanging facsimile signature pages.

[signature page follows]

 

- 1 -


IN WITNESS WHEREOF, this Amendment has been duly executed by the parties hereto as of the date first above written.

 

THE GENERAL HOSPITAL CORPORATION:       DARA THERAPEUTICS, INC.
By:  

/s/ Frances Toneguzzo

      By:  

/s/ Richard A. Franco

Print name:   Frances Toneguzzo       Print name:   Richard A. Franco
Title:   Executive Director       Title:   President
Research Ventures & Licensing        

 

- 2 -


Appendix A

PATENT RIGHTS

MGH Ref. MGH-1229.0 Borsook

 

Country

   Application
Status
   Application Serial
Number
   Filing Date    Publication
Number
   Publication
Date
   Patent
Number
   Issue Date

United States

   Granted    09/013711    1/26/1998          5,905,069    5/18/1999

PCT

   Expired –
National stage
entered
   PCT/US99/01518    1/26/1999    WO 99/37310    7/29/1999      

Australia

   Granted    2469399    1/26/1999          758342    7/3/2003

China

   Granted    99802430.9    1/26/1999          ZL99802430.9    4/21/2004

Japan

   Pending    2000-528292    1/26/1999            

MGH Ref. MGH-1725.0 Borsook

 

Country

   Application
Status
   Application Serial
Number
   Filing Date    Publication
Number
   Publication
Date
   Patent
Number
   Issue Date

United States

   Expired –
provisional
   60/234,382    9/20/2000            

United States

   Granted    10/380354    9/5/2003    04 38927    2/26/2004    7196071    3/27/2007

United States

   Granted    11/686510    3/15/2007    07 0161597    7/12/2007    7375094    5/20/2008

United States

   Pending    12/112213    4/30/2008            

PCT

   Expired –
National stage
entered
   PCT/US01/29371    9/20/2001    WO 02/24146    3/28/2002      

Canada

   Pending    2425172    9/20/2001            

Europe

   Pending    01971222.3    9/20/2001    1328236    7/23/2003      

Japan

   Pending    2002528183    9/20/2001    2004537494    12/16/2004      

 

- 3 -